Last reviewed · How we verify
Ombitasvir-Paritaprevir-Ritonavir
Ombitasvir-Paritaprevir-Ritonavir is a HCV protease inhibitor and NS5A inhibitor combination Small molecule drug developed by University of Modena and Reggio Emilia. It is currently FDA-approved for Chronic hepatitis C virus infection, genotype 1 (with or without ribavirin, depending on cirrhosis status), Chronic hepatitis C virus infection, genotype 4. Also known as: Viekirax.
This combination inhibits hepatitis C virus NS3/4A protease, NS5A protein, and uses ritonavir as a pharmacokinetic booster to increase drug levels.
This combination inhibits hepatitis C virus (HCV) NS3/4A protease, NS5A protein, and uses ritonavir as a pharmacokinetic booster to increase drug levels. Used for Chronic hepatitis C virus (HCV) infection, genotype 1 and 4.
At a glance
| Generic name | Ombitasvir-Paritaprevir-Ritonavir |
|---|---|
| Also known as | Viekirax |
| Sponsor | University of Modena and Reggio Emilia |
| Drug class | HCV protease inhibitor and NS5A inhibitor combination |
| Target | HCV NS3/4A protease, HCV NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Ombitasvir inhibits the NS5A protein essential for HCV replication, paritaprevir inhibits the NS3/4A serine protease required for viral polyprotein processing, and ritonavir inhibits CYP3A4 to boost paritaprevir concentrations. Together, these agents block multiple steps in the HCV viral lifecycle, achieving high cure rates in genotype 1 and 4 infections.
Approved indications
- Chronic hepatitis C virus infection, genotype 1 (with or without ribavirin, depending on cirrhosis status)
- Chronic hepatitis C virus infection, genotype 4
Common side effects
- Fatigue
- Headache
- Nausea
- Pruritus
- Elevated bilirubin
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
- Study of Oral Treatments for Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ombitasvir-Paritaprevir-Ritonavir CI brief — competitive landscape report
- Ombitasvir-Paritaprevir-Ritonavir updates RSS · CI watch RSS
- University of Modena and Reggio Emilia portfolio CI
Frequently asked questions about Ombitasvir-Paritaprevir-Ritonavir
What is Ombitasvir-Paritaprevir-Ritonavir?
How does Ombitasvir-Paritaprevir-Ritonavir work?
What is Ombitasvir-Paritaprevir-Ritonavir used for?
Who makes Ombitasvir-Paritaprevir-Ritonavir?
Is Ombitasvir-Paritaprevir-Ritonavir also known as anything else?
What drug class is Ombitasvir-Paritaprevir-Ritonavir in?
What development phase is Ombitasvir-Paritaprevir-Ritonavir in?
What are the side effects of Ombitasvir-Paritaprevir-Ritonavir?
What does Ombitasvir-Paritaprevir-Ritonavir target?
Related
- Drug class: All HCV protease inhibitor and NS5A inhibitor combination drugs
- Target: All drugs targeting HCV NS3/4A protease, HCV NS5A protein
- Manufacturer: University of Modena and Reggio Emilia — full pipeline
- Therapeutic area: All drugs in Virology/Hepatology
- Indication: Drugs for Chronic hepatitis C virus infection, genotype 1 (with or without ribavirin, depending on cirrhosis status)
- Indication: Drugs for Chronic hepatitis C virus infection, genotype 4
- Also known as: Viekirax
- Compare: Ombitasvir-Paritaprevir-Ritonavir vs similar drugs
- Pricing: Ombitasvir-Paritaprevir-Ritonavir cost, discount & access